当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
SHINGRIX, Zoster Vaccine Recombinant, Adjuvanted
申请企业
GlaxoSmithKline Biologicals
药品名称
SHINGRIX, Zoster Vaccine Recombinant, Adjuvanted
承诺描述
Study Zoster-062 to assess the safety, reactogenicity and immunogenicity of SHINGRIX in adults =50 years of age with a prior episode of Herpes Zoster.
承诺状态描述
The study completion date has passed and the study has not yet been completed.
报告接收日期
2020/12/21 0:00:00